Source: Annual Congress 2008 - COPD and miscellaneous
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Velthove, M. Bracke, P. Souverein, R. Schweizer, B. Leufkens, W. van Solinge (Utrecht, Netherlands). Glucocorticoid use is not associated with neutrophilia among hospitalised patients. Eur Respir J 2008; 32: Suppl. 52, 3788

Member's Comments

No comment yet.

Related content which might interest you: Increase in systemic IL-5 is associated with mepolizumab treatment failure in patients with severe asthma Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Budesonide is not associated with increased risk of pneumonia in COPD patients Source: Annual Congress 2009 - Exacerbations of COPD and bronchiectasis: aetiology and treatment Year: 2009 Statin therapy and reduced risk of pneumonia in elderly patients with diabetes Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Factors associated with frequent exacerbations in patients with severe asthma Source: Eur Respir J 2001; 18: Suppl. 33, 369s Year: 2001 Osteoporosis risk associated with chronic corticoid inhalation therapy in patients with COPD Source: Annual Congress 2009 - Prognosis and comorbidities in COPD Year: 2009 Polypharmacy in patients hospitalised for acute exacerbation of COPD Source: Eur Respir J 2014; 44: 791-794 Year: 2014 Acute bronchiolitis in hospitalised patients: inappropriate use of corticosteroids Source: Eur Respir J 2005; 26: Suppl. 49, 29s Year: 2005 Adjunctive systemic corticosteroid treatment in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019 Year: 2019 Combined therapy of severe osteoporosis for patients with bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 47s Year: 2001 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Is COPD pharmacotherapy associated with increased incidence of community-acquired pneumonia? Source: Annual Congress 2008 - Community-acquired pneumonia and COPD: what do we know? Year: 2008 Characteristics of hospitalized COVID-19 patients and parameters associated with severe pneumonia Source: Virtual Congress 2021 – COVID - 19 epidemiology Year: 2021 Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Severe asthma in old patients is characterized by signs of immunosuppression and by lymphocyte resistance to glucocorticoids Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Markers of T2-inflammation in patients with severe asthma and concomitant COPD Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease Year: 2020 Rates of asthma exacerbations are not affected by beta2-adrenergic receptor genotype in patients with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 708s Year: 2005 Role of aerosolized therapy in the incidence of cardiac rythm disturbances in patients hospitalized with a COPD exacerbation Source: Virtual Congress 2020 – Prognosis and integrated management of COPD Year: 2020 Comparing pneumonia incidence in COPD patients treated with or without inhaled corticosteroid Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data Year: 2021